UCB SA (OTCMKTS:UCBJY) Short Interest Down 95.9% in October

UCB SA (OTCMKTS:UCBJY) was the target of a large decline in short interest in October. As of October 31st, there was short interest totalling 3,000 shares, a decline of 95.9% from the October 15th total of 73,100 shares. Based on an average daily volume of 47,400 shares, the days-to-cover ratio is presently 0.1 days.

UCB Stock Performance

Shares of UCBJY traded down $0.92 during midday trading on Tuesday, hitting $98.25. 14,007 shares of the company traded hands, compared to its average volume of 18,658. The firm has a 50 day moving average of $92.95 and a 200-day moving average of $81.96. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. UCB has a 52 week low of $34.85 and a 52 week high of $99.40.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.